Skip to main content
. 2024 Oct 24;131(11):1775–1780. doi: 10.1038/s41416-024-02885-3

Table 3.

Most common adverse events in 35 participants (maximum grade per patient per event)

Adverse event Any grade, n (%) Grade 3 or 4, n (%)
Hematologic toxicity
 Anemia 18 (51.4) 6 (17.1)
 Thrombocytopenia 15 (42.9) 3 (8.6)
 Neutropenia 27 (77.1) 12 (34.3)
 Febrile neutropenia 0 0
Non-hematologic toxicity
 Nausea 33 (94.3) 0
 Vomiting 10 (28.6) 0
 Diarrhea 6 (17.1) 1 (2.9)
 Constipation 0 0
 Hypertension 4 (11.4) 0
 Fatigue 29 (82.9) 1 (2.9)
 Hand-foot syndrome 0 0
 Proteinuria 4 (11.4) 0
 ALT/AST increased 8 (22.9) 1 (2.9)